辅助治疗，首要的是不伤害：DE-VOTE试验的初步观点——比较德谷胰岛素与甘精胰岛素在2型糖尿病中的心血管安全性
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes.
作者信息
Kalra Sanjay
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, India.
出版信息
Diabetes Ther. 2017 Apr;8(2):213-217. doi: 10.1007/s13300-017-0235-x. Epub 2017 Feb 14.
Abstract
A demonstration of cardiovascular safety is mandatory for all newly developed glucose-lowering agents, including insulin analogues. The vascular benefit of insulin is evident from the Diabetes Control and Complication Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), and the cardiovascular safety of insulin glargine has been demonstrated in individuals with newly diagnosed diabetes or prediabetes in the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). The top-line results of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) have proven the cardiovascular safety of insulin degludec in persons with type 2 diabetes. In this commentary I discuss the interrelationship of insulin and cardiovascular health, while comparing the results of DEVOTE and ORIGIN.
摘要
对于所有新研发的降糖药物，包括胰岛素类似物，证明其心血管安全性是必不可少的。胰岛素的血管益处已在糖尿病控制与并发症试验（DCCT）和英国前瞻性糖尿病研究（UKPDS）中得到证实，而甘精胰岛素的心血管安全性已在“初始甘精胰岛素干预降低结局”（ORIGIN）试验中，在新诊断的糖尿病或糖尿病前期个体中得到证明。“比较德谷胰岛素与甘精胰岛素在心血管事件高风险2型糖尿病患者中的心血管安全性试验”（DEVOTE）的初步结果，已证实德谷胰岛素在2型糖尿病患者中的心血管安全性。在这篇评论中，我将讨论胰岛素与心血管健康的相互关系，同时比较DEVOTE和ORIGIN的结果。
相似文献
1
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes.辅助治疗，首要的是不伤害：DE-VOTE试验的初步观点——比较德谷胰岛素与甘精胰岛素在2型糖尿病中的心血管安全性
Diabetes Ther. 2017 Apr;8(2):213-217. doi: 10.1007/s13300-017-0235-x. Epub 2017 Feb 14.
2
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes.勘误：《辅助治疗，首要为不伤害：比较德谷胰岛素与甘精胰岛素在2型糖尿病中心血管安全性的DEVOTE试验初步观点》
Diabetes Ther. 2017 Apr;8(2):219. doi: 10.1007/s13300-017-0246-7.
3
Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.心血管结局试验更新：来自 DEVOTE 试验的见解。
Curr Diab Rep. 2018 Sep 18;18(11):102. doi: 10.1007/s11892-018-1086-1.
4
Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).开展、规划和实施期中分析：来自DEVOTE心血管结局试验的经验教训（一项比较德谷胰岛素与甘精胰岛素在心血管事件高危2型糖尿病患者中心血管安全性的试验）
Ther Innov Regul Sci. 2019 Mar;53(2):279-286. doi: 10.1177/2168479018776943. Epub 2018 May 24.
5
Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes.关注 2 型糖尿病患者的血糖波动和低血糖。
Diabetologia. 2018 Jan;61(1):43-47. doi: 10.1007/s00125-017-4421-1. Epub 2017 Sep 15.
6
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).英国德谷胰岛素对比甘精胰岛素 U100 的长期成本效果：来自 DEVOTE 试验（DEVOTE16）基础-餐时亚组的证据。
Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3.
7
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).DEVOTE 研究中的日常禁食血糖变异性：与严重低血糖和心血管结局的关联（DEVOTE2）。
Diabetologia. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15.
8
The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.德谷胰岛素对 1 型糖尿病成人患者夜间严重低血糖高风险及夜间症状性低血糖风险的影响（HypoDeg 试验）：研究原理和设计。
BMC Endocr Disord. 2019 Jul 23;19(1):78. doi: 10.1186/s12902-019-0408-x.
9
Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.BEGIN 和 EDITION 项目的临床观点：T2DM 中地特胰岛素 300U/mL 或甘精胰岛素 300U/mL 与甘精胰岛素 100U/mL 的试验水平荟萃分析结果。
Diabetes Metab. 2018 Nov;44(5):402-409. doi: 10.1016/j.diabet.2018.02.002. Epub 2018 Feb 19.
10
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.胰岛素地特胰岛素（100、200 U/mL）和甘精胰岛素（100、300 U/mL）的药代动力学和药效学特征的临床相关性-证据回顾与临床解读。
Diabetes Metab. 2019 Sep;45(4):330-340. doi: 10.1016/j.diabet.2018.11.004. Epub 2018 Nov 26.
引用本文的文献
1
The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.降糖治疗与心血管结局的全景：从贫瘠之地到繁华都市。
Biomed Res Int. 2017;2017:9257930. doi: 10.1155/2017/9257930. Epub 2017 Nov 14.
本文引用的文献
1
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.DEVOTE研究设计（比较德谷胰岛素与甘精胰岛素对心血管事件高危2型糖尿病患者心血管安全性的试验）-DEVOTE 1
Am Heart J. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18.
2
Hypoglycaemia in diabetes.
J Pak Med Assoc. 2014 Sep;64(9):1090-3.
3
The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey.低血糖对健康相关生活质量的影响：来自一项多国家时间权衡调查的加拿大结果。
Can J Diabetes. 2014 Feb;38(1):45-52. doi: 10.1016/j.jcjd.2013.09.001.
4
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.胰岛素德谷胰岛素与胰岛素甘精胰岛素在初诊 2 型糖尿病患者中的比较：一项为期 2 年的随机、以目标为导向的试验。
Diabet Med. 2013 Nov;30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30.
5
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).在 2 型糖尿病的胰岛素初治患者中，德谷胰岛素对比甘精胰岛素：一项为期 1 年、随机、以目标为导向的试验（BEGIN Once Long）。
Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.
6
Basal insulin and cardiovascular and other outcomes in dysglycemia.基础胰岛素与糖调节受损患者的心血管及其他结局。
N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
7
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.在苏格兰使用甘精胰岛素与癌症发病率：苏格兰糖尿病研究网络流行病学组的一项研究。
Diabetologia. 2009 Sep;52(9):1755-65. doi: 10.1007/s00125-009-1453-1. Epub 2009 Jul 15.
8
Does diabetes therapy influence the risk of cancer?糖尿病治疗会影响患癌风险吗？
Diabetologia. 2009 Sep;52(9):1699-708. doi: 10.1007/s00125-009-1441-5.
9
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.甘精胰岛素的使用与短期恶性肿瘤发病风险：一项基于人群的瑞典随访研究。
Diabetologia. 2009 Sep;52(9):1745-54. doi: 10.1007/s00125-009-1444-2. Epub 2009 Jul 9.
10
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.降糖治疗对 2 型糖尿病患者癌症风险的影响。
Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.
Zotero 插件